key: cord-0883795-0f1um3ua
authors: Johnson, Amanda; Vincent, Brenda; Carson, Paul; Skoy, Elizabeth
title: Prevalence of SARS-CoV-2 Antibodies Among North Dakota Community Pharmacy Personnel: A Seroprevalence Survey
date: 2021-01-21
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2021.01.023
sha: 5f2c030a612fca17e35380626c6e1ea409bb470a
doc_id: 883795
cord_uid: 0f1um3ua

Background The virus SARS-CoV-2, the cause of the COVID-19 pandemic, has disrupted much of the healthcare system. Despite changes in routine practices, community pharmacists have continuously served their patients throughout the pandemic. Frontline healthcare workers, including community pharmacy personnel are at risk of becoming infected with SARS-CoV-2. Objective The purpose of this study was to identify the seroprevalence of the SARS-CoV-2 antibodies among a sample of North Dakota community pharmacy personnel in July of 2020. Methods This observational study was conducted in two cities in North Dakota with the highest COVID-19 rates at the time of investigation. Community pharmacy personnel were tested for the presence of the SARS-CoV-2 IgG and IgM antibodies using a rapid antibody test. In addition to antibody testing, participants completed a questionnaire reporting on demographics, prior COVID-19 exposure, prior COVID-19 symptoms, and personal protection equipment (PPE) practices. Results A total of 247 pharmacy personnel from 29 pharmacies were tested for SARS-CoV-2 antibodies. The timing and use of personal protective equipment varied by location. Among the 247 community pharmacy personnel, 14.6% tested positive for IgM and/or IgG. Survey data revealed a significant association (p<0.05) between a positive antibody test and direct contact with an individual who tested positive for COVID-19 (OR: 2.65, 95% CI: 1.18, 5.95), but there were no significant effects related to the workplace, including: PPE use, personnel role or the number of hours worked. The self-reported loss of taste or smell was the only significant symptom associated with a positive antibody test (OR: 18.91, 95% CI: 3.10, 115.59). Conclusion Community pharmacy personnel may be at an increased risk for SARS-CoV-2 exposure compared to the general population.

The virus SARS-CoV-2, the cause of the COVID-19 pandemic, has disrupted much of the healthcare system. Despite changes in routine practices, community pharmacists have continuously served their patients throughout the pandemic. Frontline healthcare workers, including community pharmacy personnel are at risk of becoming infected with SARS-CoV-2.

The purpose of this study was to identify the seroprevalence of the SARS-CoV-2 antibodies among a sample of North Dakota community pharmacy personnel in July of 2020.

This observational study was conducted in two cities in North Dakota with the highest COVID-19 rates at the time of investigation. Community pharmacy personnel were tested for the presence of the SARS-CoV-2 IgG and IgM antibodies using a rapid antibody test. In addition to antibody testing, participants completed a questionnaire reporting on demographics, prior COVID-19 exposure, prior COVID-19 symptoms, and personal protection equipment (PPE) practices.

A total of 247 pharmacy personnel from 29 pharmacies were tested for SARS-CoV-2 antibodies.

The timing and use of personal protective equipment varied by location. Among the 247 community pharmacy personnel, 14.6% tested positive for IgM and/or IgG. Survey data revealed a significant association (p<0.05) between a positive antibody test and direct contact with an J o u r n a l P r e -p r o o f 4

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), which causes the COVID-19 illness, has disrupted societies worldwide. Studies have shown that after initial exposure to SARS-CoV-2, immunoglobulin M (IgM) antibodies first appear within 1 to 2 weeks, and are then followed by more durable immunoglobulin G (IgG) antibodies within approximately 2-4 weeks 1 Evidence shows that SARS-CoV-2 IgG is detected by antibody tests for more than 50 days after symptom onset, whereas, IgM commonly falls below the limits of detection approximately 36 days following symptom onset. 1 Currently it is unknown if antibodies for SARS-CoV-2 provide long-term immunity against COVID-19.

Healthcare workers have continued to work on the front lines to serve their patients during the COVID-19 pandemic. Studies have investigated the presence of SARS-CoV-2 antibodies as an indicator of healthcare exposure to the virus. A wide range of seroprevalence among frontline healthcare providers have been reported: 7.6% in Nashville, 36% in New York City, 44% in London, and 4.9% in Michigan. [2] [3] [4] [5] The majority of studies have found healthcare providers to have a greater seropositivity compared to the estimated general population ranging from 2.8 to 6.9%. [6] [7] [8] [9] Community pharmacy personnel, like other healthcare workers, have been deemed essential workers and have continued to serve their patients. In fact, during the COVID-19 pandemic, pharmacies have been called upon to expand their roles within communities through expansion of immunization practices, SARS CoV-2 testing, and point-of-care testing. 10 waiver. 13 However, the Food and Drug Administration (FDA) does not require testing to be done under a CLIA-waiver if the testing is done for surveillance purposes through a health department. The purpose of this observational study was to report the prevalence of antibodies to SARS-CoV-2 from a sample of North Dakota community pharmacy personnel.

An observational study was conducted analyzing the prevalence of SARS-CoV-2 antibodies among a convenience sample of community pharmacy personnel in the cities of Fargo and Grand Forks, North Dakota. At the time of conducting this study (July 2020) these two cities were the highest populated cities within North Dakota and located in the counties with the highest number of COVID-19 cases. 14, 15 The SARS-CoV-2 antibody test, BioSys Plus and relevant supplies, were provided from the North Dakota Department of Health to conduct this study for surveillance purposes. 16 This study was approved through the North Dakota State University Institutional Review Board (IRB).

The Biosys Plus COVID-19 IgM/IgG Rapid Test was provided an Emergency Use Authorization by the FDA, but was not CLIA-waived at the time of study. 16 It is a lateral flow immunoassay J o u r n a l P r e -p r o o f for qualitative detection and differentiation of IgG and IgM antibodies in whole blood. 16 The reported clinical sensitivity and specificity of the test is 93.5% and 100% respectively. 16 The sample requires approximately 20 microliters of blood and is obtained from the finger using a single-use lancet and pipet. Results of the antibody test can be read between 10 and 15 minutes. 16 All community pharmacy personnel in Fargo or Grand Forks were eligible to participate in the study. Pharmacy managers/owners were contacted by phone to determine interest. After consenting to participate, pharmacies were provided with a time of testing and asked to provide an approximate number of employees at each location. Personnel wishing to be tested were asked to report on the specific date and time assigned. Consent was obtained and participants completed a questionnaire (available as an online supplement) prior to testing. The questionnaire included demographic information, past personal protective equipment (PPE) practices, previous symptoms related to COVID-19, prior exposure to a person known to be positive for SARS-CoV-2, and prior tests for SARS-CoV-2 antibodies or active infection.

Participants were from 29 pharmacies, 21 in Fargo and 8 in Grand Forks, and were tested between July 20 and July 23, 2020. There are 24 community pharmacies in Fargo, and 11 in Grand Forks. Of the 35 pharmacies between the two cities, 33 agreed to participate. However, the research team ran out of allocated tests from the state health department, so were unable to provide testing to the final four locations.

Seropositivity and its associations with risk factors were assessed by Chi-square analysis.

Multiple logistic regression was used to evaluate COVID-19 symptoms significantly associated with SARS-CoV-2 antibodies. Odds ratios and corresponding 95% confidence intervals were J o u r n a l P r e -p r o o f estimated. Statistical significance was determined as a p-value < 0.05. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC). The seroprevalence did not significantly differ based on the personnel's role (cashier, technician, pharmacist, intern, or other) nor the hours worked. The use of PPE was also not a significant factor associated with seropositivity (Table 1) .

There were no self-reported COVID-19 outbreaks within any of the community pharmacies visited. There was a variance among the community pharmacies response to the pandemic and the protective measures taken. The majority of pharmacy personnel began wearing PPE in March. The most commonly used PPE was masks, with 89.5% of individuals reporting usage.

Of those who used masks, 63.8% used surgical masks and 36.2% used cloth masks. Other PPE included: plexiglass, closing the lobby, glove usage and goggles/face shields.

Out of the 36 pharmacy workers who were seropositive, 16 (44.4%) were asymptomatic. The loss of sense of taste or smell was the only symptom of COVID-19 that was significantly associated with seroconversion (OR: 18.91, 95% CI: 3.10, 115.59) (Figure 1 ). Difficulty J o u r n a l P r e -p r o o f breathing, chills, runny nose, shortness of breath, fatigue, headache, body aches, sore throat, fever, or cough were not significantly associated with seroconversion.

This is the first reported study examining the SARS-CoV-2 seroprevalence in community pharmacy personnel. When comparing our study to other studies that examined the seroprevalence of the general population, community pharmacists appear to have a much greater seroprevalence (14.6% vs 2.8-6.9%). [6] [7] [8] [9] In addition, published seroprevalence for United States healthcare professionals range from 4.9 to 36% with the highest rate being in New York City.

However, these studies have been conducted within healthcare systems and not community settings and within varying population densities. 2, 3, 5 Although, to date, there have not been any widespread SARS-CoV-2 seroprevalence studies completed in North Dakota, one could also compare our findings to those from the nucleic acid test used to detect the SARS-CoV-2 virus. As of July 31, 2020 there was a cumulative of 12,319 positive tests for the SARS-CoV-2 virus, and a 14 day rolling average positivity rate of 2.74% for North Dakota residents. 15 SARS-CoV-2 spread in North Dakota was primarily through community contact, followed closely by close contact. 15 Almost half of the seropositive pharmacy workers were asymptomatic. This demonstrates the importance of utilizing PPE. Furthermore, since there were not any reported outbreaks within the pharmacies, this could indicate that the PPE was effective in preventing the spread of infection among personnel. Not unexpected, previously testing positive by a nucleic acid test, prior exposure to a positive COVID-19 case, and loss of the sense of taste or smell were associated with antibody positivity. Notable was that differing roles within a pharmacy and the number of hours worked, were not associated with antibody positivity, which may be due to limited sample size.

There were some limitations to our study. First, there is the potential for false negatives or false positives. Any line on the BioSys Plus was considered a positive result regardless of the intensity, so faint lines could have been read as negative. To diminish the potential for error, all test results were confirmed by the two individuals conducting the test. With a sensitivity of 93.5% and 36 positive cases, it is estimated that approximately 38-39 were truly positive so approximately 3 false negatives would be expected. However, this is not enough to change the findings. In addition, the small sample size and low prevalence of SARS-CoV-2 led to low power to detect differences between those that were seropositive and seronegative. In addition, the BioSys plus is known to have potential cross-reaction with other common coronavirus J o u r n a l P r e -p r o o f strains: HKU1, NL63, OC43, or 299E. 6 Unfortunately, there is not statewide data to compare community pharmacy personnel seroprevalence to seroprevalence of the general population.

Therefore, comparisons must be made to other studies conducted in other states. In addition, we do not have data about the percentage of pharmacy personnel who volunteered to get tested.

Participants volunteered to enroll in the study, so there may have been bias associated with decision to enroll. Furthermore, the self-report nature of the questionnaire may have been another source of bias. Finally, this study was conducted in two cities within one state, so therefore our sample is not representative of all community pharmacy personnel.

Seropositivity for the SARS-CoV-2 virus was higher among community pharmacy personnel than estimated regional samples of the general population and measured seropositivity in other groups of healthcare workers. Greater attention and more studies in community pharmacy personnel are needed, as this population may be at a higher risk of exposure to the SARS-CoV-2 virus.

J o u r n a l P r e -p r o o f Note: r denotes reference category. Early PPE access refers to those pharmacies that provided personal protective equipment before April 2020. All comparisons are unadjusted.

Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak. Virol Sin

Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19

Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment

Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample -Indiana

Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States

COVID-19) in the U.S. Centers for Disease Control and Prevention

Community Pharmacists' Contributions to Disease Management During the COVID-19 Pandemic

Guidance for PREP Act Coverage for Qualified Pharmacy Technicians and State-Authorized Pharmacy Inters for Chilhood Vaccines, COVID-19 Vaccines

Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic

COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19. FDA

North Dakota Commerce: Demographics. North Dakota Department of Commerce

North Dakota Coronavirus Cases. Department of Health

BioSys Plus COVID-19 IgM/IgG Rapid Test

Substantial underestimation of SARS-CoV-2 infection in the United States